

LEVANTE CAPITAL REACHES ITS FIRST MILESTONE BY INVESTING IN INSILICOTRIALS
completing the € 3 mil. Round A , to boost the Company's expansion on Asian Markets.

Sept. the 21st 2020, Milan – [Levante Capital](#) – the upcoming Italian VC Vehicle which focuses on expanding the reach of European Tech onto Asian Markets - is announcing today its first investment in InSilicoTrials, the cloud-based simulation healthcare company.

The € 350K ticket investment and – most importantly – Levante's established extended Network in Asia will boost InSilicoTrials' presence in the Healthcare Modeling & Simulation markets of China and South Korea initially.

The investment also kicks off Levante Capital's investment strategy that regards Asia as an intrinsic frontline for South European Innovative Initiatives that are aiming to become true Global Champions, while turning their stakeholders into true Global Players as well.

[InSilicoTrials](#) – as the name suggests – operates in the segment of clinical trials through computer simulations. Through the development of artificial models, researchers are able to assess the safety, efficacy, and risks of biomedical devices and pharmacological treatments with a view to their commercialization. While Simulation Modeling is an established approach in many industries, it is still a novelty when it comes to Pharma. That is the window of opportunity identified by Luca Emili and Roberta Bursi, Founder and Co-Founder of InSilicoTrials. It is a market made of 60K+ companies worldwide, growing constantly each year that will reach € 6.5 bn within 2025, ready to receive the company's scalable and cloud-based solution that will democratize access to simulations in healthcare.

“our investment in InSilicoTrials is for Levante Capital the first strong validation of our thesis:” – says Francesco Rossi, one of the three Partners of Levante, “firstly that Southern-European and Italian innovative initiatives are world-class disruptive forces and that Asia is the right stage for those technologies to emerge as Global Market Champions. Secondly that our value proposition is totally synergic for the ecosystem we are in. We act as a “waypoint” for upcoming tech-companies to reach a still largely unexplored scalable market.”

“Covid-19 has clearly identified the limits of current drug development processes: in a hyper-connected world it's impossible to wait for year to have a working solution against new health menaces” says Luca Emili, InSilicoTrials CEO “Simulation opens up a vast array of future-proof scenarios where molecular checks can be accelerated as far as 50%, while radically reducing animal and human testing. Even Regulators are embracing this opportunity, pushing for standardisation through GSP definitions (Good Simulation Practices), on which InSilicoTrials is constantly engaged. As an Italian Startup we have been able already to setup meaningful relations in Europe and USA, now thanks to Levante Capital we are opening the doors to Asia – a strategic and ever-growing market.”

ABOUT LEVANTE CAPITAL

[Levante Capital](#) is an Independent Technology Investment Vehicle envisioned to invest in South-European disruptive companies that have in Asia their main strategic growth stage. Founded in late 2019 by Edoardo Agamennone, Francesco Lorenzini and Francesco Rossi, Levante Capital is the direct expression of the Founders team's track-record in Asia operations, including: Institutional cooperation for the development of European Tech in China, 20+ club deals on Italian Early stage startups, 30+ companies accelerated in China and 40+ years of combined professional experience on the European-Asian vector.

ABOUT INSILICOTRIALS

[InSilicoTrials](#) is a company founded in 2017 in Trieste by Luca Emili and Roberta Bursi. InSilicoTrials aims to revolutionize the pharmaceutical and biomedical sector, offering the first web platform in the world that democratizes access to tested and validated simulation models for the clinical trial of drugs and medical devices.

It is based on two key elements: on the one hand, the company works with researchers, regulatory agencies, and universities around the world to identify the best mathematical models available for the medical sector. These models are then integrated into the web platform, which becomes a constantly growing catalog. The second part consists precisely in making the models usable in a simple way, within a secure IT infrastructure and by personnel who, while having a high level of scientific preparation, are not necessarily experts in modeling & simulation.

The InSilicoTrials team is composed of engineers and computer scientists with extensive experience and know-how in the research and development processes of medical devices and pharmaceuticals, modeling, numerical simulation in biomedical and biomechanical, health regulations and regulations, and IT development.

Press Office Levante

hello@levantecapital.eu

www.levantecapital.eu

Press Office InsilicoTrials

Clara Zambetti

clara.zambetti@insilicotrials.com

www.insilicotrials.com